EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte Studie

Influence of major hepatectomy on gemcitabine-based chemotherapy for recurrent biliary tract cancer after surgery: a subgroup analysis of JCOG1113

Tatsuya Okuno, Chigusa Morizane, Junki Mizusawa, Hiroaki Yanagimoto, Satoshi Kobayashi, Hiroshi Imaoka, Takeshi Terashima, Hisato Kawakami, Yusuke Sano, Takuji Okusaka, Masafumi Ikeda, Masato Ozaka und 13 weitere

International Journal of Clinical Oncology · 2025

DOI: 10.1007/s10147-024-02642-9 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Tatsuya Okuno und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Faculty of Medicine, Kindai University, Osakasayama City, 377-2, Ohno-Higashi, Osaka, 589-8511, Japan. t-okuno@pg7.so…. Hauptthemen laut MEDLINE: Gemcitabine, Deoxycytidine, Biliary Tract Neoplasms, Hepatectomy. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Major hepatectomy (MH) can increase the risk of adverse events (AEs) owing to impaired drug metabolism due to decreased liver volume and surgical injury. Thus, we performed this subgroup analysis using data from JCOG1113, a phase III trial comparing gemcitabine plus S-1 (GS) and gemcitabine plus cisplatin (GC) in patients with advanced and recurrent biliary tract cancer (BTC), to evaluate the effect of MH on the safety and efficacy of GC and GS regimens in patients with recurrent BTC. METHODS: Of the 354 patients with advanced BTC enrolled in JCOG1113, 76 patients with postoperative recurrence (30 in the MH group and 46 in the non-MH group) were analyzed. RESULTS: Grade ≥ 3 platelet count decreased in both arms was more frequent in the MH group than in non-MH group (GC, 0.0 vs. 17.6%; GS, 3.9 vs. 15.4%). However, in the MH group, the white blood cell decreased (GC, 55.0 vs. 38.5%; GS, 23.1 vs. 7.7%) and anemia (GC, 15.0 vs. 11.8%; GS, 23.1 vs. 7.7%) were less common than in the non-MH group. The MH and non-MH groups showed no significant difference in overall survival (OS) in both GC [median OS, 23.0 in MH vs. 16.9 months in non-MH (hazard ratio, 0.857; 95% CI 0.387-1.899)], and GS [median OS, 21.5 vs. 14.9 months (hazard ratio, 0.670; 95% CI 0.310-1.447)] arms. CONCLUSIONS: The safety and efficacy of gemcitabine-based chemotherapy were comparable between patients who underwent MH and those who underwent other surgeries.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GemcitabineDeoxycytidineBiliary Tract NeoplasmsHepatectomyNeoplasm Recurrence, LocalTegafurAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedCisplatinOxonic AcidDrug CombinationsAdult

Stichwörter der Autor:innen

Biliary tract cancersChemotherapyMajor hepatectomy

Substanzen

GemcitabineDeoxycytidineTegafurCisplatinS 1 (combination)Oxonic AcidDrug Combinations

Autor:innen und Institutionen

  • Department of Medical Oncology, Faculty of Medicine, Kindai University, Osakasayama City, 377-2, Ohno-Higashi, Osaka, 589-8511, Japan. t-okuno@pg7.so-net.ne.jp.
  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Surgery, Division of Hepato-Biliary-Pancreatic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
  • Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
  • Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Zitieren

APA

Okuno, T., Morizane, C., Mizusawa, J., Yanagimoto, H., Kobayashi, S., Imaoka, H., Terashima, T., Kawakami, H., Sano, Y., Okusaka, T., Ikeda, M., Ozaka, M., Miwa, H., Todaka, A., Shimizu, S., Mizuno, N., Sekimoto, M., Sano, K., Tobimatsu, K., …, & Ueno, M. (2025). Influence of major hepatectomy on gemcitabine-based chemotherapy for recurrent biliary tract cancer after surgery: a subgroup analysis of JCOG1113. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02642-9

Vancouver

Okuno T, Morizane C, Mizusawa J, Yanagimoto H, Kobayashi S, Imaoka H, et al. Influence of major hepatectomy on gemcitabine-based chemotherapy for recurrent biliary tract cancer after surgery: a subgroup analysis of JCOG1113. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-024-02642-9

BibTeX
@article{Okuno2025,
  author = {Okuno, Tatsuya and Morizane, Chigusa and Mizusawa, Junki and Yanagimoto, Hiroaki and Kobayashi, Satoshi and Imaoka, Hiroshi and Terashima, Takeshi and Kawakami, Hisato and Sano, Yusuke and Okusaka, Takuji and Ikeda, Masafumi and Ozaka, Masato and Miwa, Haruo and Todaka, Akiko and Shimizu, Satoshi and Mizuno, Nobumasa and Sekimoto, Mitsugu and Sano, Keiji and Tobimatsu, Kazutoshi and Katanuma, Akio and Gotoh, Kunihito and Yamaguchi, Hironori and Ishii, Hiroshi and Furuse, Junji and Ueno, Makoto},
  title = {Influence of major hepatectomy on gemcitabine-based chemotherapy for recurrent biliary tract cancer after surgery: a subgroup analysis of JCOG1113},
  journal = {International Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1007/s10147-024-02642-9}
}
Kostenlos starten →